Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 19/20 | 0.61 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437916 | 1.00 | AGTR2 (0.61) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL29047260 | 0.93 | AGTR2 (0.62) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL23121256 | 0.92 | AGTR2 (0.60) | AGTR2AGTR1CYP2C9 | |
| SCHEMBL29437909 | 0.92 | AGTR2 (0.60) | AGTR2AGTR1CYP2C9 | |
| SCHEMBL29047290 | 0.91 | AGTR2 (0.58) | AGTR2AGTR1 | |
| SCHEMBL25250583 | 0.90 | AGTR2 (0.55) | AGTR2AGTR1 | |
| SCHEMBL23120747 | 0.89 | AGTR2 (0.50) | AGTR2 | |
| SCHEMBL29700571 | 0.89 | AGTR2 (0.50) | AGTR2 | |
| SCHEMBL25248583 | 0.88 | AGTR2 (0.55) | AGTR2 | |
| SCHEMBL29047252 | 0.88 | AGTR2 (0.57) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348444-A1 | NOVEL COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | VICORE PHARMA AB (SE) | 2023-11-02 | — | — | US | claimed |
| EP-4208460-A1 | NOVEL COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | Vicore Pharma AB (SE) | 2023-07-12 | — | — | EP | claimed |
| WO-2022049372-A1 | NOVEL COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | VICORE PHARMA AB (SE) | 2022-03-10 | — | — | WO | claimed |
| EP-4208460-A1 | NOVEL COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | Vicore Pharma AB (SE) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022049372-A1 | NOVEL COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | VICORE PHARMA AB (SE) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348444-A1 | NOVEL COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | AGTR1, AGTR2, REN | AGTR2 2/4885AGTR1 1/4885CYP2C9 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.